Cumberland Partners Ltd Makes New Investment in Zoetis Inc. $ZTS

Cumberland Partners Ltd bought a new position in Zoetis Inc. (NYSE:ZTS) in the 1st quarter, Holdings Channel.com reports. The fund bought 8,900 shares of the company’s stock, valued at approximately $1,052,000.

Other institutional investors have also modified their holdings of the company. Prosperity Bancshares Inc bought a new stake in Zoetis in the fourth quarter valued at about $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in Zoetis during the first quarter valued at approximately $28,000. Lodestone Wealth Management LLC bought a new position in Zoetis during the 4th quarter worth approximately $30,000. Root Financial Partners LLC lifted its holdings in Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after buying an additional 103 shares during the last quarter. Finally, Elyxium Wealth LLC acquired a new position in shares of Zoetis in the 4th quarter worth approximately $32,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Several firms announced or promoted securities-fraud litigation against Zoetis, which can weigh on sentiment by raising legal, financial, and reputational risk for the company. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: The class-action deadline reminders may keep the controversy in the spotlight and encourage more shareholder claims, adding overhang to the stock. ZOETIS CLASS ACTION DEADLINE MONDAY JULY 27th
• Neutral Sentiment: One Seeking Alpha commentary argues Zoetis sentiment remains strong and fundamentals are improving, offering a more constructive longer-term view. Zoetis: Sentiment Keeps Winning As Fundamentals Improve

Zoetis Stock Up 1.0%

Shares of Zoetis stock opened at $75.32 on Friday. The stock has a market capitalization of $31.58 billion, a price-to-earnings ratio of 12.49, a PEG ratio of 1.18 and a beta of 0.75. Zoetis Inc. has a twelve month low of $71.47 and a twelve month high of $160.48. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The business’s 50 day simple moving average is $77.29 and its 200-day simple moving average is $104.25.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.87 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. Zoetis’s payout ratio is 35.16%.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of research analyst reports. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Argus reaffirmed a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Citigroup decreased their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a report on Monday, May 18th. UBS Group dropped their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Finally, HSBC reduced their price target on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $119.50.

Insider Activity

In other news, Director Michael B. Mccallister bought 3,000 shares of Zoetis stock in a transaction on Monday, May 11th. The stock was purchased at an average cost of $77.76 per share, with a total value of $233,280.00. Following the purchase, the director directly owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Frank A. Damelio purchased 6,650 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the purchase, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders bought 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by company insiders.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.